Fractional CO2 laser treatment as adjunctive therapy to topical steroids for managing vulvar lichen sclerosus
Kristen Stewart, Sunbal Javaid, Konika P Schallen, Sarah Bartlett, Nancy A Carlson, Kristen Stewart, Sunbal Javaid, Konika P Schallen, Sarah Bartlett, Nancy A Carlson
Abstract
Objectives: Uncontrolled vulvar lichen sclerosus (VLS) is often associated with distressful symptoms of genital itch, irritation, and pain and can lead to a pathological process including anatomical changes, scarring, and an elevated risk of cancer in the genital area. First-line topical corticosteroid as monotherapy is frequently not adequate to fully suppress disease activity and control symptoms. This study evaluated the efficacy of fractional CO2 laser treatments as adjunctive therapy where recalcitrant VLS had been improved, but not adequately controlled, with topical corticosteroid treatment. Outcomes were evaluated up to 12 months after a series of CO2 laser treatments delivered via a fractional handpiece.
Materials and methods: Women with a diagnosis of VLS supported by histologic findings on biopsy and/or clinical signs on physical examination received up to five monthly laser treatments. Subjects maintained existing topical corticosteroid and any exogenous hormone treatment during the study. Investigators assessed severity (0 = not present, 1 = mild, 2 = moderate, or 3 = severe) of clinical signs and architectural changes present before adjunctive study interventions and at follow-up visits. Subjects reported the presence of clinical symptoms and impact on quality of life on 4- or 5-point Likert scales. The validated Female Sexual Function Index (FSFI) was used to assess changes in sexual function. Four subjects were biopsied before adjunctive laser treatment and at follow-up.
Results: Twelve females, 11 postmenopausal, with a mean age of 57 ± 10 years received three to five monthly CO2 laser treatments. Significant improvement in all prominent clinical signs and architectural changes were reported at the 3- and 6-month follow-ups after the treatment series. Significant improvement was maintained at the 12-month follow-up, with 89% of subjects showing at least one-point improvement in elasticity compared to baseline; 86% in lichenification; 88% in sclerosis; and 80% in whitening and parchment-like skin. Labial fusion and the extent of disease improved in 50% of patients. Ulcerations present in three subjects at baseline resolved after treatment. Subjects reported 86% improvement in dyspareunia and 83% in skin tearing. Quality of life improved significantly after treatment (p < 0.01). The 6-month follow-up FSFI showed significant improvement in sexual function compared to baseline (p < 0.05), with a mean point improvement of 4.5. Histology findings after treatment showed some positive improvement, as a decrease in dermal hyalinized zone thickness. There were no treatment complications or adverse events related to the treatment.
Conclusions: Fractional CO2 laser treatment outcomes showed improvement in predominant clinical signs and architectural changes in VLS recalcitrant to topical corticosteroid treatment. Adjunctive laser treatment relieved symptoms and improved quality of life as well as sexual function. Fractional CO2 laser treatment may provide an advanced treatment modality for the management of recalcitrant VLS with improved patient care and sustainable outcomes. Further study in a larger population and with CO2 laser treatment to both vulvar tissue and the vaginal canal should be explored.
Keywords: fractional CO2 laser; sexual dysfunction; topical corticosteroids; vulvar dermatoses; vulvar lichen sclerosus.
Conflict of interest statement
Kristen Stewart will receive an honorarium for this article. Sunbal Javaid receives speaker honoraria. Konika P. Schallen is an employee of Candela; the work for this study was carried out at her private clinic. The remaining authors declare that there are no conflict of interests.
© 2021 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.
Figures
References
- Fistarol SK, Itin PH. Diagnosis and treatment of lichen sclerosus: an update. Am J Clin Dermatol. 2013;14(1):27–47.
- Pérez‐López FR, Vieira‐Baptista P. Lichen sclerosus in women: a review. Climacteric. 2017;20(4):339–47.
- Fruchter R, Melnick L, Pomeranz MK. Lichenoid vulvar disease: a review. Int J Womens Dermatol. 2017;3(1):58–64.
- Singh N, Ghatage P. Etiology, clinical features, and diagnosis of vulvar lichen sclerosus: a scoping review. Obstet Gynecol Int. 2020;2020:7480754.
- Haefner HK, Aldrich NZ, Dalton VK, Gagné HM, Marcus SB, Patel DA, et al. The impact of vulvar lichen sclerosus on sexual dysfunction. J Women's Health (Larchmt). 2014;23(9):765–70.
- Van de Nieuwenhof HP, Meeuwis KA, Nieboer TE, Vergeer MC, Massuger LF, De Hullu JA. The effect of vulvar lichen sclerosus on quality of life and sexual functioning. J Psychosom Obstet Gynaecol. 2010;31(4):279–84.
- Preti M, Scurry J, Marchitelli CE, Micheletti L. Vulvar intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1051–62.
- Halonen P, Jakobsson M, Heikinheimo O, Riska A, Gissler M, Pukkala E. Lichen sclerosus and risk of cancer. Int J Cancer. 2017;140(9):1998–2002.
- Akel R, Fuller C. Updates in lichen sclerosus: British Association of Dermatologists guidelines for the management of lichen sclerosus 2018. Br J Dermatol. 2018;178(4):823–4.
- Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosus. Cochrane Database Syst Rev. 2011;2011(12):CD008240.
- Coondoo A, Phiske M, Verma S, Lahiri K. Side‐effects of topical corticosteroids: a long overdue revisit. Indian Dermatol Online J. 2014;5(4):416–25.
- Lee A, Bradford J, Fischer G. Long‐term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatol. 2015;151(10):1061–7.
- Athanasiou S, Pitsouni E, Antonopoulou S, Zacharakis D, Salvatore S, Falagas ME, et al. The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women. Climacteric. 2016;19(5):512–8.
- Salvatore S, Leone Roberti Maggiore U, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015;22(8):845–9.
- Samuels JB, Garcia MA. Treatment to external labia and vaginal canal with CO2 laser for symptoms of vulvovaginal atrophy in postmenopausal women. Aesthet Surg J. 2019;39(1):83–93.
- Lee A, Lim A, Fischer G. Fractional carbon dioxide laser in recalcitrant vulvar lichen sclerosus. Australas J Dermatol. 2016;57(1):39–43.
- Kroft J, Shier M. A novel approach to the surgical management of clitoral phimosis. J Obstet Gynaecol Can. 2012;34:465–71.
- Hurliman E, Zelickson B, Kenkel J. In‐vivo histological analysis of a fractional CO2 laser system intended for treatment of soft tissue. J Drugs Dermatol. 2017;16(11):1085–90.
- Sheinis M, Selk A. Development of the adult vulvar lichen sclerosus severity scale—a Delphi consensus exercise for item generation. J Low Genit Tract Dis. 2018;22(1):66–73.
- Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self‐report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.
- Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, et al. Assessment of pain. Br J Anaesth. 2008;101(1):17–24.
- Omi T, Numano K. The role of the CO2 laser and fractional CO2 laser in dermatology. Laser Ther. 2014;23(1):49–60.
- Prignano F, Campolmi P, Bonan P, Ricceri F, Cannarozzo G, Troiano M, et al. Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair. Dermatol Ther. 2009;22(suppl 1):S8–15.
- Alexiades MR. Fractional CO2 laser treatment of the vulva and vagina and the effect of postmenopausal duration on efficacy. Lasers Surg Med. 2021;53(2):185–98.
- Arroyo C. Fractional CO2 laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women. Int J Women's Health. 2017;9:591–5.
- Palacios S, Ramirez M. Efficacy of the use of fractional CO2RE Intima laser treatment in stress and mixed urinary incontinence. Eur J Obstet Gynecol Reprod Biol. 2020;244:95–100.
- Kartamaa M, Reitamo S. Treatment of lichen sclerosus with carbon dioxide laser vaporization. Br J Dermatol. 1997;136(3):356–9.
- Peterson CM, Lane JE, Ratz JL. Successful carbon dioxide laser therapy for recalcitrant anogenital lichen sclerosus. Dermatol Surg. 2004;30(8):1148–51.
- Pagano T, Conforti A, Buonfantino C, Schettini F, Vallone R, Gallo A, et al. Effect of rescue fractional microablative CO2 laser on symptoms and sexual dysfunction in women affected by vulvar lichen sclerosus resistant to long‐term use of topic corticocorticosteroid: a prospective longitudinal study. Menopause. 2020;27(4):418–22.
- Tadir Y, Gaspar A, Lev‐Sagie A, Alexiades M, Alinsod R, Bader A, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med. 2017;49(2):137–59.
- Bond DS, Vithiananthan S, Leahey TM, Thomas JG, Sax HC, Pohl D, et al. Prevalence and degree of sexual dysfunction in a sample of women seeking bariatric surgery. Surg Obes Relat Dis. 2009;5(6):698–704.
- Mendieta‐Eckert M, Torrontegui Bilbao J, Zabalza Estévez I, Landa Gundin N. Treatment of vulvar lichen sclerosus et atrophicus with fractional carbon dioxide laser therapy: a report of 4 cases. Actas Dermosifiliogr (Engl Ed). 2021;112(1):85–8.
- Krapf JM, Mitchell L, Holton MA, Goldstein AT. Vulvar lichen sclerosus: current perspectives. Int J Women's Health. 2020;12:11–20.
Source: PubMed